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Prevention is still the best approach to stroke. Th e goal of prevention is to reduce stroke risk by reducing 
it’s risk factors. Th e most common risk factors inclu-
de hypertension, elevated serum lipids, myocardial 
infarction, atrial fi brillation and carotid stenosis, di-
abetes, smoking and alcohol consumption, inappro-
priate diet and inadequate physical activity. However, 
recently more and more attention turns to new risk 
factors for stroke such as lipid fractions, subclinical 
carotid artery disease, thickening of the intima and 
media of the carotid arteries, increased body mass in-
dex, increased waist to hips ratio, infection and infl a-
mmation, hyperhomocysteinemia and genetic factors, 
because the conventional risk factors can not explain 
the occurrence of almost a third of all strokes. Th e 
most signifi cant classic risk factors remain elevated 
blood pressure and hyperlipoproteinemia, especially 
hypercholesterolemia. Both disorders are widespread 
in the population, and today we have eff ective me-
dication for both disorders so they can be adequately 
treated, and thus stroke risk could be reduced.
It has long been known that treatment of hyper-
tension and hypercholesterolemia has a very impor-
tant role both in primary and in secondary prevention 
of stroke. In recent years the results of large randomi-
zed clinical trials have been published and have reli-
ably shown that lowering blood pressure and elevated 
cholesterol level is associated with a signifi cant reduc-
tion in stroke risk. In addition, it seems that the newer 
generations of antihypertensives (eg. ACE inhibitors, 
calcium channel blockers, angiotensin receptor bloc-
kers) may have benefi cial eff ect on reducing stroke 
risk, in addition to reducing the blood pressure. ACE 
inhibitors and angiotensin receptor blockers can im-
prove endothelial function and slow the progression 
of atherosclerosis. Calcium channel antagonists, that 
are highly lipophilic, have some antioxidant properti-
es. Results in animal models have shown that statins 
reduce oxidation of LDL particles and their entry into 
the cells of the arterial wall. Amlodipine, lacidipine 
and nifedipine suppress platelet production in patients 
suff ering from hypertension and have potential anti-
atherosclerotic properties.
Th ere is also evidence that statins might have ad-
ditional benefi cial eff ects in preventing stroke, with 
their benefi cial eff ect on lowering cholesterol levels. It 
appears that statins, by reducing cholesterol, promote 
vasodilatation, stabilize plaque, aff ect the infl amma-
tory response in endothelial cells, reduce blood clots 
production and reduce the adhesion of platelets to the 
ruptured plaque. Other anti-atherosclerotic properti-
es of statins include reducing accumulation of infl am-
matory cells in plaques, inhibiting the proliferation of 
smooth muscle cell wall, inhibiting platelet function, 
and improving vascular endothelial function. Based 
on the above, we can assume that a wider use of newer 
antihypertensives and statins may signifi cantly im-
prove the prevention of cerebrovascular disease and 
especially stroke.
